Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks with high potential. On October 3, Piper Sandler raised the firm’s price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) to $31 from $21 while keeping an Overweight rating on the shares. The rating update came after the firm hosted Ocular Therapeutix Inc.’s (NASDAQ:OCUL) management at an investor dinner after its investor day, discussing aspects such as the newly disclosed diabetic retinopathy pivotal trial designs and the anticipate ...